20 hours ago
1
TipRanks
Tue, December 30, 2025 astatine 7:05 AM CST 1 min read
Needham raised the firm’s price target connected Autolus Therapeutics (AUTL) to $11 from $10 and keeps a Buy standing connected the shares. The steadfast besides names Autolus a apical prime for 2026. While Aucatzyl’s motorboat has been awesome with $76M successful sales, investors stay skeptical of Autolus, questioning if the institution tin scope breakeven, the expert tells investors successful a probe note. Needham disagrees with skepticism, saying the shares offers an “attractive valuation” and a “strong accidental for worth instauration successful 2026.” Data from the the FELIX survey and obe-cel results successful relapsed/refractory acute lymphoblastic leukemia bespeak an expanding addressable market, contends the firm. Its modeling has Autolus reaching breakeven by 2028 based connected Aucatzyl income alone. Needham believes obe-cel successful lupus nephritis receives small designation astatine existent stock levels, which could alteration with objective updates successful the archetypal fractional of 2026.
-
Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
-
Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential
Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>
See Insiders’ Hot Stocks connected TipRanks >>
Read More connected AUTL:
Disclaimer & DisclosureReport an Issue
-
Autolus Therapeutics presents information from CATULUS Phase 1 proceedings of obe-cel
-
Autolus Therapeutics Appoints Ryan Richardson to Board
-
Autolus Therapeutics appoints Ryan Richardson to committee of directors
-
Midday Fly By: Alphabet continues ascent, fueled by AI optimism
-
Autolus Therapeutics announces NICE draught guidance recommending Aucatzyl
English (CA) · 
English (US) · 
Spanish (MX) ·